GRACE :: Lung Cancer

FGFR and Its Role in Treating Squamous Cell Lung Cancer

Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.

What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?

“HSP 90 inhibitors are a really cool class of drugs…” states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.

The Promise of Immunotherapy in Lung Cancer

Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.

DDR2 Mutations in Squamous Cell Lung Cancer

A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.

University of Colorado’s Online Screening for Rare Lung Cancer Subtypes Opens Door to New Kind of Clinical Trial

The following piece is from the University of Colorado, where Dr. Camidge and some others there are leading a very novel trial for a small molecularly defined subgroup with specific biomarkers related to fibroblast growth factor receptor-1 (FGFR1) are potential candidates for a trial just launching now with the agent ponatinib, a tyrosine kinase inhibitor (TKI) that hits many targets.  This is a new approach, trying to reach an audience of patients through the internet, and I’m hopeful it will succeed in giving patients a novel treatment opportunity and in moving research along faster.

————————————- Continue reading

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content


Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Other Resources